Slide 1: Earnings call Q4 2025
Devyser Earnings call Q4 2025 February 12, 2025
Slide 2: Today's presenters
Today’s presenters Jan Wahlström Sabina Berlin Theis Kipling CEO CFO CCO
Slide 3: Devyser Q4 result – Positive EBIT for the full year
Devyser Q4 result – Positive EBIT for the full year
Slide 4: Fourth quarter financials
Fourth quarter financials Revenue • Sales 72.0 MSEK (64.2 MSEK) • Growth 12.1%, F/X adjusted 20,9% • Thermo order came in as expected giving us a distributor sales increase of 28% in the quarter and 23% in FY Gross margin 79.5% for the quarter EBIT 18.0 MSEK, 25% for the quarter. Cash positi
Slide 5: Financials Jan-Dec
Financials Jan-Dec Revenue • Sales 250.5 MSEK (216.9 MSEK) • Growth 15.5%, 20,2% FX adjusted. Gross margin 80.6%, EBIT 10.1 MSEK (-62,3 MSEK). • EBIT margin 4% Cash position 77.5 MSEK 5
Slide 6: Strong sales and good cost control deliver result
Strong sales and good cost control deliver result · Sales growth in local currency over 20% · Re-organization delivers improved profitability, this quarter had over 20% EBIT and full year EBIT was positive · Sales supported in the quarter by Thermo orders and a strong finish in Italy · Cost focus an
Slide 7: Devyser acquires CyberGene AB
Devyser acquires CyberGene AB
Slide 8: Product launches in Q4
Product launches in Q4 · CFTR IVDR launched, our biggest development project to date o Will support coming projects moving from RUO and IVDD to IVDR · CMS (Centers for Medicare and Medicaid Services) price set for RHD tests.
Slide 9: More highlights
More highlights · MolDx feedback o The work has taken longer time than expected o More clinical data was required, and we have worked on improving the clinical evidence. o We expect to re-submit after the summer 2026 · FDA path for Accept o First patient in Devyser Accept cfDNA studie o We have star
Slide 10: Fourth quarter 2025
Fourth quarter 2025
Slide 11: Fourth quarter
Fourth quarter Revenue • Sales 72.0 MSEK (64.2 MSEK) • Growth +12.1% 11
Slide 12: Rolling 12 months net sales
Rolling 12 months net sales MSEK 300 250 200 150 100 50 0 12
Slide 13: Sales by region
Sales by region EMEA 64,6 54,0 209,4 192,0 Asia-Pacific 2,2 1,5 74 7,0 North and South 51 87 336 179 America Total 72,0 64,2 250,5 216,9 Dvysr.
Slide 14: Sales by sales channel
Dvysr. Sales by sales channel Direct sales 43,8 36,8 168,5 151,3 60,8% 57,3% 19,2% Distributor sales 28,1 27,4 82,0 65,6 39,0% 42,7% 2,6% Total 72,0 64,2 250,5 216,9 100,0% 100,0% 12,1%
Slide 15: Fourth quarter
Fourth quarter Revenue • Sales 70.0 MSEK (64.2 MSEK) • Growth +12.1% Gross margin 79.5% (84.4%) 15
Slide 16: Fourth quarter
Fourth quarter Revenue • Sales 70.0 MSEK (64.2 MSEK) • Growth +12.1% Gross margin 79.5% (84.4%) EBIT • 18.0 MSEK (-3.7) 16
Slide 17: Fourth quarter
Fourth quarter Revenue • Sales 70.0 MSEK (64.2 MSEK) • Growth +12.1% Gross margin 79.5% (84.4%) EBIT • 18.0 MSEK (-3.7) Strong financial position • 77.5 MSEK in liquidity • No debts 17
Slide 18: Highlights Q4 and Commercial outlook
Highlights Q4 and Commercial outlook
Slide 19: Q4 commercial recap
Q4 commercial recap · A record high quarter with 72m SEK revenues and Full Year surpassing 250m SEK driven by growth across all segments · Italy delivered double digit growth which is consistent with prior years and keeps taking market share · North America more than doubled FY revenues vs 2024 desp
Slide 20: Devyser becomes an Illumina "Systems Integrator"
Devyser becomes an Illumina “Systems Integrator” · On January 28th Devyser became an Illumina Systems integrator with Pan-European rights to sell their new MiSeq i100 instrument and consumables · This opens up for selling reagent rental agreements where we combine the instrument and consumables with
Slide 21: Update on Thermo Fisher Scientific
Update on Thermo Fisher Scientific Q4 was a strong quarter as expected and Thermo Fisher continues to bring in more customers We continue to accelerate customer onboarding as well as market adoption of especially cfDNA In Europe we are making significant progress related to having cfDNA become
Slide 22: North America update
Devyser Genomic Laboratories We are increasing the samples related to the MolDx submission Cyted collaboration is following plan – revenues and volumes are consistently increasing Strong interest from companies to adopt the same way of partnering North as we do with Cyted RHD testing remai
Slide 23: Europe
• Italy grew with double digits in 2025 and continues to take market share which we expect will continue not least fueled by the new Illumina agreement. • The demand for IVDR certified products increases Europe consistently • The Illumina agreement broadens our play in Europe and strengthens our pos
Slide 24: Devyser goes fully direct in Spain
Devyser goes fully direct in Spain · As of January 1st 2026 Devyser will go direct in Spain as we have taken over all customers from our distributor(s) · We have been collaborating with our distributors to address the existing customers and had one for our Fragment analysis portfolio and another for
Slide 25: Going forward
Going forward • Execute on our strategy – now delivering one EBIT quarter above long term target and 3 quarters in row with positive EBIT. • Capitalize on our launched products and continue our RnD efforts to launch new products in 2026 • Continue to work on organizational efficiency • Continue our
Slide 26: Q&A
O&A Dvysr.
Slide 27: Thank you!
Thank you! Connect with us www.devyser.com